No abstract

No abstract

BackgroundParacetamol is the first choice for antipyretic or analgesic treatment throughout pregnancy. Products with Paracetamol are readily available over the counter and therefore easily accessible for self-medication. Epidemiological data on Paracetamol intake pattern during pregnancy and its potential immunological effects are sparse. We aimed to analyze a possible association between Paracetamol medication and numbers of hematopoietic stem cells (HSC) in cord blood.MethodsThe objective was addressed in the PRINCE (PRENATAL DETERMINANTS OF CHILDREN'S HEALTH) study, a population-based prospective pregnancy cohort study initiated in 2011 at the University Medical Center in Hamburg, Germany. 518 healthy pregnant women with singleton pregnancies were recruited during the first trimester. Three examinations were scheduled at the end of the 1st (gestational week 12–14), the 2nd (gestational week 22–24) and the 3rd trimester (gestational week 34–36). For 146 of these women, cord blood flow cytometry data were available. Paracetamol intake was assessed for each trimester of pregnancy.FindingsAmong the 518 enrolled women, 40% took Paracetamol as main analgesic treatment during pregnancy. The intake frequency and dosage of Paracetamol varied between the women and was overall low with a tendency towards higher frequencies and higher dosages in the third trimester. Paracetamol intake, particularly during the third trimester, resulted in decreased relative numbers of HSCs in cord blood, independent of maternal age, first-trimester BMI, parity, gestational age and birth weight (− 0.286 (95% CI − 0.592, 0.021), p = 0.068).InterpretationPrenatal Paracetamol intake, especially during the third trimester, may be causally involved in decreasing HSCs in cord blood.

No abstract

Abstract Background: European countries report large differences in coronavirus disease (COVID-19) case fatality risk (CFR). CFR estimates depend on demographic characteristics of the cases, time lags between reporting of infections and deaths and infrastructural characteristics, such as healthcare and surveillance capacities. Methods: We used publicly available data from official reports of the national health authorities of Germany, Italy, France, and Spain on COVID-19. These include age-specific numbers of cases and deaths for different dates, which we used to compute age-standardized CFR ratios using a standard European population for standardization. Moreover, we investigated the impact of different potential time lags on the estimation of the CFR using data published by the European Centre for Disease Prevention and Control (ECDC). Finally, we described the association between case fatality and the intensive care bed capacity.Results: We found that age-standardized CFR estimates increased from the beginning of March to mid-May 2020 in all included European countries. In Germany, CFRs are lower than in other countries. However, the differences are much larger when comparing the crude risks rather than the age-adjusted risks. Thus, the different age distribution of the cases account for a major proportion of the reported differences. Case fatality estimates using time lags of 1-10 days converged in all countries over time, however, there is no optimal time lag to assess the CFR during the pandemic. Time lags that provided the most constant estimates and approach best the observed CFR after the pandemic ranged from 5-10 days in different countries and at different time points during the pandemic. For the association between intensive care bed capacity and fatality we found that days with a high need for intensive care beds were positively correlated with daily hospitalization fatality in France, Italy, and Spain, but not in Germany. Conclusions: Our results highlight that cross-country comparisons of crude CFR estimates can be misleading and should be avoided. However, to adjust for potential sources of bias more disaggregated data and information on surveillance and health care capacities are needed. Filling these gaps and harmonizing data across European countries will facilitate further analysis.

European countries report large differences in coronavirus disease (COVID-19) case fatality risk (CFR). CFR estimates depend on demographic characteristics of the cases, time lags between reporting of infections and deaths and infrastructural characteristics, such as healthcare and surveillance capacities. We discuss the impact of these factors on the CFR estimates for Germany, Italy, France, and Spain for the COVID-19 pandemic from early March to mid-April, 2020. We found that, first, a large proportion of the difference in CFRs can be attributed to different age structures of the cases. Second, lags of 5-10 days between day of case report and death should be used, since these provide the most constant estimates. Third, for France, Italy, and Spain, intensive care beds occupied by COVID-19 patients were positively associated with fatality risks of hospitalized cases. Our results highlight that cross-country comparisons of crude CFR estimates can be misleading and should be avoided.

Even though several SARS-CoV-2 vaccines have shown high effectiveness in the prevention of COVID-19 in healthy subjects, vaccination response in patients with plasma-cell-related disorders (PCD) remains widely unknown. Here, we report on an analysis describing the serological response after prime-boost SARS-CoV-2 vaccination in PCD patients, as compared to a healthy control group, and on possible influencing factors of serological responses. Blood samples were analyzed for the presence of quantitative anti-SARS-CoV-2 spike RBD Ig. A total of 82 patients were included; 67 received mRNA-, eight vector-based and four heterologous vaccinations. SARS-CoV-2 antibody titers (SP-AbT) were assessed in a mean of 23 days (SD ± 11 days) after the first and in a mean 21 days (SD ± 9) after prime-boost vaccination. A positive SP-AbT was detected in 31.9% of PCD patients after the first vaccination, and in 88.9% (44/49) after prime-boost vaccination, which was significantly less likely than that in the control group (100%, 78/78) (p = 0.008). Furthermore, we have been able to validate our previously suggested threshold of 30 CD19+ B lymphocytes/µL as being predictive for SP-AbT development. Despite anti-CD38 directed therapy, quadruplet treatment, higher age and missing deep remission, which correlated negatively with SP-AbT appearance, SP-AbT formation is possible in a majority of myeloma patients after prime-boost vaccination.

Bis zum Jahr 2020 gab es für Deutschland keinen repräsentativen Sex-Survey mit publizierten Daten. Die GeSiD-Studie „Gesundheit und Sexualität in Deutschland“ ist der erste bundesweite, repräsentative Sex-Survey. Anliegen dieses Kurzbeitrags ist es, eine Einführung zur Studie und zu ihren verschiedenen Untersuchungsbereichen zu geben. Die Ausgangslage wird geschildert und ein Einblick in das methodische Vorgehen gegeben. Ausgewählte Ergebnisse der Studie werden vorgestellt und mögliche neue Fragestellungen für Folgeuntersuchungen vorgeschlagen. Für die GeSiD-Studie wurden im Zeitraum von 2018 bis 2019 insgesamt 4955 Personen (2336 Männer, 2619 Frauen) im Alter von 18–75 Jahren befragt. Die computergestützten Face-to-Face-Interviews hatten einen umfangreichen Selbstausfüllerteil und erfragten ein breites Themenspektrum sexueller Verhaltensweisen und sexueller Gesundheitsdaten. Es wurden Daten zu sexueller Identität, Beziehungen, sexuellem Verhalten und sexueller Gesundheit erhoben. Diese zeigen unter anderem, dass nur eine Minderheit der Befragten jemals mit einem Arzt oder einer Ärztin über HIV/Aids oder andere sexuell übertragbare Infektionen (STI) gesprochen hat. Die Studie zeigt den weiterhin deutlichen Bedarf an Aufklärung, Informationsvermittlung und Fortbildungen im Themenfeld sexueller Gesundheit.